- Home
- BUI vs AUTL Comparison
BUI vs AUTL Comparison
Compare BUI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BUI | AUTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.8M | 596.2M |
| IPO Year | 2011 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BUI | AUTL |
|---|---|---|
| Price | $24.91 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 75.2K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $24.58 | $1.18 |
| 52 Week High | $30.80 | $2.58 |
Technical Indicators
Market Signals| Indicator | BUI | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 28.60 | 37.56 |
| Support Level | $24.85 | $1.37 |
| Resistance Level | $27.85 | $1.92 |
| Average True Range (ATR) | 0.35 | 0.09 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 14.07 | 5.17 |
Price Performance
Historical ComparisonAbout BUI BlackRock Utility Infrastructure & Power Opportunities Trust
BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure, and Power Opportunities business segments anywhere in the world and by employing writing (selling) call and put options.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.